Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Reference: Zongertinib for her2 Mutated NSCLC
Multicohort, open-label, phase 1a–1b trial (Beamion LUNG-1, NCT04886804) Previously treated advanced or metastatic HER2-mutant NSCLC Zongertinib 120 mg daily (selected dose) in p
New Protocol: TFOX for Advanced Gastric Cancer
Phase 3, open-label, multicenter randomized trial (PRODIGE 51- FFCD-GASTFOX) Pts with previously untreated advanced HER2-negative gastric/GEJ adenocarcinoma TFOX (docetaxel + oxali
New Reference: RiTUXimab alone for Follicular Lymphoma
Randomised, open-label, phase 3 trial (NCT00112931) Advanced stage (II–IV), asymptomatic, low tumour burden follicular lymphoma (grade 1–3a) Watchful waiting vs. rituximab indu
New Reference: Neoadjuvant FOLFOX + Panitumumab for Colon Cancer
Randomised, open-label, embedded phase II trial (FOxTROT) Resectable, locally advanced colon adenocarcinoma (T3-4, N0-2, M0) in RAS/BRAF-wildtype patients Neoadjuvant FOLFOX + pani
New Protocol: Neoadj Pembrolizumab + TP for her2+ Breast Cancer
Single-arm, phase 2 trial (WSG-KEYRICHED-1, NCT03988036) Patients with HER2-positive early-stage (cT1c-T3/N0-1/M0) breast cancer Pembrolizumab + trastuzumab + pertuzumab for 12 wks
New Indication: Neoadjuvant Durvalumab with CISplatin/Gemcitabine for Upper GU Tract Cancer
Phase 2, multicenter, open-label, nonrandomized trial (iNDUCT-GETUG V08) High-risk, operable upper tract urothelial carcinoma (UTUC), M0, eligible for radical nephroureterectomy Du
New Reference: Neoadjuvant Dostarlimab for dMMR Tumors
Phase 2, single-arm, multicenter study (NCT04165772) Patients with stage I-III dMMR solid tumors amenable to curative surgery, including rectal and nonrectal sites Neoadjuvant dost
New Reference: Belzutifan for vHL Associated Tumors
Single-arm, phase 2 trial (LITESPARK-004) VHL disease patients with RCC, CNS hemangioblastomas, or pancreatic NETs Belzutifan 120 mg orally once daily
New Protocol: Atezolizumab with Carbo-Pem-Bev for Pleural Mesothelioma
Randomized, open-label, phase 3 trial (BEAT-meso) Unresectable, untreated pleural mesothelioma patients Atezolizumab + cisplatin + pemetrexed + bevacizumab (Atezo-CPB) vs. cisplati
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.